- Home
- GRX vs INZY Comparison
GRX vs INZY Comparison
Compare GRX & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRX
- INZY
- Stock Information
- Founded
- GRX 2007
- INZY 2015
- Country
- GRX United States
- INZY United States
- Employees
- GRX N/A
- INZY N/A
- Industry
- GRX Finance/Investors Services
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- GRX Finance
- INZY Health Care
- Exchange
- GRX Nasdaq
- INZY Nasdaq
- Market Cap
- GRX 160.2M
- INZY 188.2M
- IPO Year
- GRX N/A
- INZY 2020
- Fundamental
- Price
- GRX $9.89
- INZY $1.00
- Analyst Decision
- GRX
- INZY Strong Buy
- Analyst Count
- GRX 0
- INZY 10
- Target Price
- GRX N/A
- INZY $16.90
- AVG Volume (30 Days)
- GRX 39.7K
- INZY 557.8K
- Earning Date
- GRX 01-01-0001
- INZY 03-10-2025
- Dividend Yield
- GRX 5.98%
- INZY N/A
- EPS Growth
- GRX N/A
- INZY N/A
- EPS
- GRX 0.26
- INZY N/A
- Revenue
- GRX N/A
- INZY N/A
- Revenue This Year
- GRX N/A
- INZY N/A
- Revenue Next Year
- GRX N/A
- INZY N/A
- P/E Ratio
- GRX $38.50
- INZY N/A
- Revenue Growth
- GRX N/A
- INZY N/A
- 52 Week Low
- GRX $7.73
- INZY $0.98
- 52 Week High
- GRX $10.40
- INZY $7.80
- Technical
- Relative Strength Index (RSI)
- GRX 40.84
- INZY 29.50
- Support Level
- GRX $9.92
- INZY $0.98
- Resistance Level
- GRX $10.23
- INZY $1.10
- Average True Range (ATR)
- GRX 0.13
- INZY 0.10
- MACD
- GRX -0.01
- INZY 0.01
- Stochastic Oscillator
- GRX 10.53
- INZY 6.16
About GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest
Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.